- Home
- IDYA vs WGS Comparison
IDYA vs WGS Comparison
Compare IDYA & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- WGS
- Stock Information
- Founded
- IDYA 2015
- WGS 2017
- Country
- IDYA United States
- WGS United States
- Employees
- IDYA N/A
- WGS N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- WGS Retail: Computer Software & Peripheral Equipment
- Sector
- IDYA Health Care
- WGS Technology
- Exchange
- IDYA Nasdaq
- WGS Nasdaq
- Market Cap
- IDYA 2.2B
- WGS 2.4B
- IPO Year
- IDYA 2019
- WGS N/A
- Fundamental
- Price
- IDYA $24.27
- WGS $119.87
- Analyst Decision
- IDYA Strong Buy
- WGS Strong Buy
- Analyst Count
- IDYA 13
- WGS 7
- Target Price
- IDYA $51.36
- WGS $99.29
- AVG Volume (30 Days)
- IDYA 1.1M
- WGS 988.8K
- Earning Date
- IDYA 08-05-2025
- WGS 07-29-2025
- Dividend Yield
- IDYA N/A
- WGS N/A
- EPS Growth
- IDYA N/A
- WGS N/A
- EPS
- IDYA N/A
- WGS 0.05
- Revenue
- IDYA $7,000,000.00
- WGS $362,321,000.00
- Revenue This Year
- IDYA $101.44
- WGS $22.16
- Revenue Next Year
- IDYA $263.37
- WGS $19.63
- P/E Ratio
- IDYA N/A
- WGS $2,540.29
- Revenue Growth
- IDYA N/A
- WGS 48.70
- 52 Week Low
- IDYA $13.45
- WGS $28.86
- 52 Week High
- IDYA $40.74
- WGS $123.11
- Technical
- Relative Strength Index (RSI)
- IDYA 52.57
- WGS 70.52
- Support Level
- IDYA $22.09
- WGS $102.97
- Resistance Level
- IDYA $24.75
- WGS $123.22
- Average True Range (ATR)
- IDYA 1.25
- WGS 6.99
- MACD
- IDYA -0.13
- WGS 1.96
- Stochastic Oscillator
- IDYA 40.05
- WGS 87.25
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.